Ampersand is a venture capital firm that focuses on investing in and accelerating growth for healthcare entrepreneurs.

Ampersand

Motive Partners is a specialist private equity platform that combines investors, operators, and innovators to build, back, and buy technology companies that enable the financial economy. They invest across stages in technology-enabled financial and business services in North America and Europe.

Motive Partners

SOLITERM Group GmbH designs, manufactures, installs, and maintains industrial-grade turnkey high temperature solar powered energy systems for cooling, process steam, heating, electricity generation, and desalination using proprietary parabolic trough collector (PTC) technology.

SOLITERM Group GmbH

Founded in 1988, Ampersand is a middle-market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. 

Consistent with our theme of increasing specialization as a source of differentiated performance, Ampersand’s Healthcare portfolio has been focused around several overlapping industry clusters where our multiple prior successes give us a competitive edge. Most of our portfolio companies have revenues between $10 and $200 million at the time of Ampersand’s investment. We typically invest between $10 and $200 million and years of operational expertise to drive each investment toward success.

Ampersand’s team has decades of operating experience in Healthcare companies and over 150 years of shared private equity experience. Our unusual combination of skills, including deep industry, technical, financial, operating, and transactional capabilities, make us a preferred partner for entrepreneurs because we can contribute to their success on multiple levels.

At our roots, we are company-builders, not investment managers. Our experience gives us empathy for our CEOs and helps us understand the challenges they face. This ability to identify, and contribute to, problem resolution makes us very effective in our companies.

Azurity Pharmaceuticals

Endeca

FirstRain

GENEWIZ

Nexcelom Bioscience

Genome Diagnostics

Avista Pharma

Bako Diagnostics

Bioventus

Blue Sky Biotech

LakePharma

Magellan Diagnostics

Brammer Bio

Canopy Biosciences

Ampersand Capital Partners

Shoutout to our incredible Ampersand Capital Partners team and all the financial services companies who came together for the 2024 Boston YPEM Cornhole Classic! 🎉 While our Ampersand colleagues may not have made the podium, the event was a huge success, raising over $20,000 to support Expect Miracles Foundation - Financial Services Against Cancer in providing crucial financial assistance to young cancer survivors. 🙌
A big thank you to everyone who donated to make a difference in the lives of others. #ExpectMiracles #CommunityImpact #TeamAmpersand

Ampersand Capital Partners is proud to be named a GrowthCap Top Private Equity Firm of 2024! We are grateful to our partners who helped make this recognition possible. For over 35 years, we believe our deep experience, strategic insight, and collaborative relationships with CEOs, management teams, and industry advisors have driven strong outcomes in the healthcare and life sciences companies in which we invest. This recognition reflects more than just financial success - it underscores our firm’s culture, growth, and commitment to creating long-standing value. See the press release and related disclaimer: https://lnkd.in/ewrcmhKn

Congratulations, Resolian, on being nominated for the Life Sciences Queensland Ltd (LSQ) 2024 GENE Award, Company of the Year!

Welcome, Shehnaz Jaffar Kataria, Chief Financial Officer of StageBio! “Shehnaz’s history of implementing progressive growth strategies will be a pivotal and valuable asset to the StageBio team,” shares David Bruning, President/CEO of StageBio.

Congratulations to Phosphorex , a leading drug delivery-focused CDMO and Ampersand Capital Partners portfolio company, on their strategic investment from NOF AMERICA CORPORATION. The partnership will accelerate the establishment of Phosphorex’s cGMP capabilities, paving the way for enhanced collaboration and innovation in nanoparticle-based drug delivery on a global scale.

Ampersand Capital Partners portfolio company iuvo BioScience has earned four impressive audit awards for their dedication to upholding the highest standards of excellence and compliance in clinical research and lab services.

Metric
Company Name	Ampersand	Motive Partners	SOLITERM Group GmbH
Symbol
MSH ID	COM:AMPERSANDCAPITAL	COM:MOTIVEPARTNERS	COM:SOLITERMGROUP
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Technology	Energy
Industry	Venture Capital	Venture Capital and Private Equity	Renewable Energy
Country	US	US	DE
Stage
Employee Count	46	11	11
Website	ampersandcapital.com	motivepartners.com	solitermgroup.com
LinkedIn	ampersand-capital-partners	motive-partners
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic			174
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score		95.92
28-Day Growth Score		96.36
90-Day Growth Score		93.93
365-Day Growth Score		96.40

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AMPERSANDCAPITAL

Ampersand

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue